---
title: "iSpecimen (ISPC) news: reverse split, offering and merger"
url: "https://aibio.space/companies/ispecimen/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "ISPC reverse split, offering and merger news: iSpecimen plans 1-for-40 reverse stock split effective April 27, 2026. iSpecimen Inc."
---

ISPC iSpecimen Inc. NASDAQ · United States

# iSpecimen (ISPC) news ISPC reverse split, offering and merger news

Listings · 2026-09-08

## [iSpecimen gets until November 25, 2026 to meet Nasdaq equity rule](https://aibio.space/news/ispecimen-gets-until-november-25-2026-meet-nasdaq-equity-rule/)

The company plans a public offering of approximately $5 million, and its projections show stockholders' equity of approximately $5.1 million through June 30, 2027.

## Latest iSpecimen news

1. 2026-09-04 Listings [iSpecimen agrees to buy Foldlab AI software assets for $4,500,000](https://aibio.space/news/ispecimen-agrees-buy-foldlab-ai-software-assets-4-500-000/) The deal pays $2,000,000 in cash, including milestone payments, and $2,500,000 in stock held in a five-year escrow.
2. 2026-08-12 Company Updates [iSpecimen signs $2,000,000 investor relations consulting agreement](https://aibio.space/news/ispecimen-signs-2-000-000-investor-relations-consulting-agreement/) IR Agency LLC will provide news distribution for up to ten releases over a three-month term, and the fee is fully earned on receipt.
3. 2026-08-06 Financings [iSpecimen prices $5 million public offering at $1.30 per share](https://aibio.space/news/ispecimen-prices-5-million-public-offering-1-30-share/) E.F. Hutton & Co. is the exclusive placement agent, and the offering is expected to close on August 7, 2026.
4. 2026-06-10 Debt Financing [BioRestorative sets up $1,000,000 revolving loan from Bowery Group](https://aibio.space/news/biorestorative-sets-up-1-000-000-revolving-loan-bowery-group/) BioRestorative Therapies can borrow up to $1,000,000 from Bowery Group LLC at 12%, and the same agreement brought three director resignations and three new directors designated by the lender. Its cash use in 2025 was $10.8 million.
5. 2026-05-08 Listings [iSpecimen prices $2.5 million private placement at $5.12 per share](https://aibio.space/news/ispecimen-prices-2-5-million-private-placement-5-12-share/) E.F. Hutton & Co. is the exclusive placement agent, and the company expects the offering to close on or about May 11, 2026.
6. 2026-04-24 Listings [iSpecimen plans 1-for-40 reverse stock split effective April 27, 2026](https://aibio.space/news/ispecimen-plans-1-40-reverse-stock-split-effective-april-27-2026/) After the split, the company's 52,639,796 shares become 1,316,032 shares, and the stock trades split-adjusted from April 28, 2026.

## iSpecimen at a glance

- **Ticker**: ISPC

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $4.4 million

### Related companies

- [IQVIA HOLDINGS INC.](https://aibio.space/companies/iqvia/) NYSE: IQV
- [STAAR SURGICAL CO](https://aibio.space/companies/staar-surgical/) NASDAQ: STAA
- [ANGIODYNAMICS INC](https://aibio.space/companies/angiodynamics/) NASDAQ: ANGO
- [HEALTHY EXTRACTS INC.](https://aibio.space/companies/healthy-extracts/) OTC: HYEX
- [CV Sciences](https://aibio.space/companies/cv-sciences/) OTC: CVSI
- [Cannabis Bioscience International Holdings](https://aibio.space/companies/cannabis-bioscience-international/) OTC: CBIH
- [OmniAb](https://aibio.space/companies/omniab/) NASDAQ: OABI
- [LUDWIG ENTERPRISES, INC.](https://aibio.space/companies/ludwig-enterprises/) OTC: LUDG

### Also on NASDAQ

- [Keros Therapeutics](https://aibio.space/companies/keros-therapeutics/) KROS
- [FibroBiologics](https://aibio.space/companies/fibrobiologics/) FBLG
- [IRIDEX CORP](https://aibio.space/companies/iridex/) IRIX
- [Arbutus Biopharma](https://aibio.space/companies/arbutus-biopharma/) ABUS
- [Yarrow Bioscience](https://aibio.space/companies/yarrow-bioscience/) YARW
- [Axogen](https://aibio.space/companies/axogen/) AXGN

## iSpecimen annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | [$1.9 million](https://www.sec.gov/Archives/edgar/data/1558569/000121390026038607/) | [$9.3 million](https://www.sec.gov/Archives/edgar/data/1558569/000121390026038607/) |
| Research and development |  | [$1.5 million](https://www.sec.gov/Archives/edgar/data/1558569/000121390025031639/) |
| Net income (loss) | [-$10.5 million](https://www.sec.gov/Archives/edgar/data/1558569/000121390026038607/) | [-$12.5 million](https://www.sec.gov/Archives/edgar/data/1558569/000121390026038607/) |
| Cash from operations | [-$4.2 million](https://www.sec.gov/Archives/edgar/data/1558569/000121390026038607/) | [-$8.3 million](https://www.sec.gov/Archives/edgar/data/1558569/000121390026038607/) |
| Cash and equivalents | [$6.9 million](https://www.sec.gov/Archives/edgar/data/1558569/000121390026038607/) | [$1.9 million](https://www.sec.gov/Archives/edgar/data/1558569/000121390026038607/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $4.4 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about iSpecimen

Did iSpecimen do a reverse stock split?

Our latest story on this, dated Apr 24, 2026: "iSpecimen plans 1-for-40 reverse stock split effective April 27, 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/ispecimen-plans-1-40-reverse-stock-split-effective-april-27-2026/).

Has iSpecimen raised money recently?

Our latest story on this, dated Sep 8, 2026: "iSpecimen gets until November 25, 2026 to meet Nasdaq equity rule". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/ispecimen-gets-until-november-25-2026-meet-nasdaq-equity-rule/).

Is iSpecimen involved in a merger or acquisition?

Our latest story on this, dated Sep 4, 2026: "iSpecimen agrees to buy Foldlab AI software assets for $4,500,000". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/ispecimen-agrees-buy-foldlab-ai-software-assets-4-500-000/).

What is the ticker symbol of iSpecimen?

iSpecimen Inc. trades under the ticker ISPC on NASDAQ.

Where is iSpecimen listed?

iSpecimen Inc. is listed on NASDAQ.

Which country or territory is iSpecimen listed under?

Our directory records iSpecimen Inc. under United States.

Does aibio.space cover iSpecimen?

aibio.space lists iSpecimen Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

What was iSpecimen's revenue last year?

$1.9 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is iSpecimen profitable?

iSpecimen Inc. reported a net loss of $10.5 million for the fiscal year ended Dec 31, 2025, and used $4.2 million of cash in operations, per its annual report to the SEC.

How much cash does iSpecimen have?

$4.4 million in cash at Jun 30, 2026, per its 10-Q.

What is the latest iSpecimen (ISPC) stock news?

Our latest story on iSpecimen, dated Sep 8, 2026: "iSpecimen gets until November 25, 2026 to meet Nasdaq equity rule". The company plans a public offering of approximately $5 million, and its projections show stockholders' equity of approximately $5.1 million through June 30, 2027. [Source](https://aibio.space/news/ispecimen-gets-until-november-25-2026-meet-nasdaq-equity-rule/).

How long will iSpecimen's cash last?

From our story of May 8, 2026: The release also cites the risk that the company may not maintain compliance with the continued listing standards of The Nasdaq Capital Market, the substantial doubt about its ability to continue as a going concern, and its need for additional financing. [Source](https://aibio.space/news/ispecimen-prices-2-5-million-private-placement-5-12-share/).

Which other companies' news mentions iSpecimen?

iSpecimen is named in 1 of our story about other companies, most recently: "BioRestorative sets up $1,000,000 revolving loan from Bowery Group" (Jun 10, 2026). [Source](https://aibio.space/news/biorestorative-sets-up-1-000-000-revolving-loan-bowery-group/).

How can I follow iSpecimen (ISPC) news?

Press Follow on this page to add iSpecimen to your Following list, or subscribe to the aibio.space newsletter. We have published 7 stories naming iSpecimen so far, in Company Updates, Debt Financing, Financings, Listings.

## Investor discussion: iSpecimen

Members talk about iSpecimen (ISPC). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at iSpecimen, newest first. Each line links the filing it comes from.

1. 2026-10-30 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1558569/000121390026114426/ea0309612-01.htm)
2. 2026-10-09 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1558569/000121390026108501/ea0308253-8k_ispaceimen.htm)
3. 2026-09-14 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1558569/000121390026099770/ea0298075-02.htm)
4. 2026-09-10 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1558569/000121390026098847/ea0305069-8k_ispecimen.htm)
5. 2026-09-04 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1558569/000121390026097765/ea0298075-01.htm)
6. 2026-06-24 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1558569/000121390026071550/ea0295798-s1_ispecimen.htm)
7. 2026-06-01 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1558569/000121390026063575/ea0292875-8k_ispecimen.htm)
8. 2026-05-18 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1558569/000121390026058047/ea0291208-nt10q_ispecimen.htm)
9. 2026-05-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,3.01,3.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/ea029014301ex99-1.htm)
10. 2026-05-01 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1558569/000121390026051013/ea028825801ex99-1.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ISPC on TradingView](https://www.tradingview.com/symbols/NASDAQ-ISPC/).

## Listing details

iSpecimen Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ISPC, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: iSpecimen Inc.

- **Ticker**: ISPC

- **Listing**: NASDAQ

- **Country or territory**: United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/ispecimen/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "iSpecimen (ISPC) news: reverse split, offering and merger", 2026-10-31, https://aibio.space/companies/ispecimen/